Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis

Qili Qiangxin capsule (QQC) is a formulation of traditional Chinese medicine commonly used for the treatment of heart failure in China. This meta-analysis aimed to assess the clinical efficacy of QQC combined with western medicine in the treatment of chronic heart failure (CHF). We conducted a syste...

Full description

Bibliographic Details
Main Authors: Xiaoming Xu, Yang Yang, Gendong Zhou, Zhengxuan Du, Xiaohong Zhang, Wei Mao, Hongwen Cai
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Evidence-Based Complementary and Alternative Medicine
Online Access:http://dx.doi.org/10.1155/2021/9761159
id doaj-ef6a6b55b15845feb59745f44c5c4c76
record_format Article
spelling doaj-ef6a6b55b15845feb59745f44c5c4c762021-08-23T01:32:10ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-42882021-01-01202110.1155/2021/9761159Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-AnalysisXiaoming Xu0Yang Yang1Gendong Zhou2Zhengxuan Du3Xiaohong Zhang4Wei Mao5Hongwen Cai6Department of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyQili Qiangxin capsule (QQC) is a formulation of traditional Chinese medicine commonly used for the treatment of heart failure in China. This meta-analysis aimed to assess the clinical efficacy of QQC combined with western medicine in the treatment of chronic heart failure (CHF). We conducted a systematic review and meta-analysis abided by the PRISMA guidelines. Literature search was conducted in the China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journals Database, PubMed, and Web of Science from inception to August 2020. A total of 52 eligible studies were obtained, and 42 of these studies were included in the meta-analysis. The results showed that, compared with western medicine alone, the combination of Qili Qingxin capsule and Western medicine treatment has better efficacy (metoprolol: RR: 1.24, 95%CI 1.14–1.34; carvedilol: RR: 1.24, 95%CI 1.14–1.34; trimetazidine: RR: 1.20, 95%CI: 1.12–1.27; sacubitril valsartan sodium: RR: 1.23, 95%CI: 1.11–1.36; sodium nitroprusside: RR: 1.33, 95%CI: 1.23–1.45; and bisoprolol: RR: 1.31, 95%CI: 1.15–1.49) and increased the level of LVEF, LVEDD, and 6MWT of patients with CHF and reduced the adverse effects and the level of HR, LVESD, BNP, and Hs-cTnT as well. However, there is high heterogeneity in the meta-analysis of LVEDV, BNP, NT-proBNP, Hs-cTnT, 6MWT, and adverse effects, and the methodological quality of the included studies was poor. Therefore, further studies with good methodological quality and large sample size are required to validate our findings. In our study, evidence suggests that Qili Qiangxin capsule combined with Western medicine may improve therapeutic effect and the quality of life of patients with CHF.http://dx.doi.org/10.1155/2021/9761159
collection DOAJ
language English
format Article
sources DOAJ
author Xiaoming Xu
Yang Yang
Gendong Zhou
Zhengxuan Du
Xiaohong Zhang
Wei Mao
Hongwen Cai
spellingShingle Xiaoming Xu
Yang Yang
Gendong Zhou
Zhengxuan Du
Xiaohong Zhang
Wei Mao
Hongwen Cai
Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
Evidence-Based Complementary and Alternative Medicine
author_facet Xiaoming Xu
Yang Yang
Gendong Zhou
Zhengxuan Du
Xiaohong Zhang
Wei Mao
Hongwen Cai
author_sort Xiaoming Xu
title Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
title_short Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
title_full Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
title_fullStr Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
title_full_unstemmed Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
title_sort clinical efficacy of qili qiangxin capsule combined with western medicine in the treatment of chronic heart failure: a systematic review and meta-analysis
publisher Hindawi Limited
series Evidence-Based Complementary and Alternative Medicine
issn 1741-4288
publishDate 2021-01-01
description Qili Qiangxin capsule (QQC) is a formulation of traditional Chinese medicine commonly used for the treatment of heart failure in China. This meta-analysis aimed to assess the clinical efficacy of QQC combined with western medicine in the treatment of chronic heart failure (CHF). We conducted a systematic review and meta-analysis abided by the PRISMA guidelines. Literature search was conducted in the China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journals Database, PubMed, and Web of Science from inception to August 2020. A total of 52 eligible studies were obtained, and 42 of these studies were included in the meta-analysis. The results showed that, compared with western medicine alone, the combination of Qili Qingxin capsule and Western medicine treatment has better efficacy (metoprolol: RR: 1.24, 95%CI 1.14–1.34; carvedilol: RR: 1.24, 95%CI 1.14–1.34; trimetazidine: RR: 1.20, 95%CI: 1.12–1.27; sacubitril valsartan sodium: RR: 1.23, 95%CI: 1.11–1.36; sodium nitroprusside: RR: 1.33, 95%CI: 1.23–1.45; and bisoprolol: RR: 1.31, 95%CI: 1.15–1.49) and increased the level of LVEF, LVEDD, and 6MWT of patients with CHF and reduced the adverse effects and the level of HR, LVESD, BNP, and Hs-cTnT as well. However, there is high heterogeneity in the meta-analysis of LVEDV, BNP, NT-proBNP, Hs-cTnT, 6MWT, and adverse effects, and the methodological quality of the included studies was poor. Therefore, further studies with good methodological quality and large sample size are required to validate our findings. In our study, evidence suggests that Qili Qiangxin capsule combined with Western medicine may improve therapeutic effect and the quality of life of patients with CHF.
url http://dx.doi.org/10.1155/2021/9761159
work_keys_str_mv AT xiaomingxu clinicalefficacyofqiliqiangxincapsulecombinedwithwesternmedicineinthetreatmentofchronicheartfailureasystematicreviewandmetaanalysis
AT yangyang clinicalefficacyofqiliqiangxincapsulecombinedwithwesternmedicineinthetreatmentofchronicheartfailureasystematicreviewandmetaanalysis
AT gendongzhou clinicalefficacyofqiliqiangxincapsulecombinedwithwesternmedicineinthetreatmentofchronicheartfailureasystematicreviewandmetaanalysis
AT zhengxuandu clinicalefficacyofqiliqiangxincapsulecombinedwithwesternmedicineinthetreatmentofchronicheartfailureasystematicreviewandmetaanalysis
AT xiaohongzhang clinicalefficacyofqiliqiangxincapsulecombinedwithwesternmedicineinthetreatmentofchronicheartfailureasystematicreviewandmetaanalysis
AT weimao clinicalefficacyofqiliqiangxincapsulecombinedwithwesternmedicineinthetreatmentofchronicheartfailureasystematicreviewandmetaanalysis
AT hongwencai clinicalefficacyofqiliqiangxincapsulecombinedwithwesternmedicineinthetreatmentofchronicheartfailureasystematicreviewandmetaanalysis
_version_ 1721199057044504576